Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06745687CT.gov BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Smoldering Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| CM336 (this asset) | Institute of Hematology & Blood Diseases Hospital, China | N/A | D · 30 |
| Dexasone | Regeneron Pharmaceuticals | P3 | BB |
| Nivestim | Regeneron Pharmaceuticals | P3 | BB |
| Lenalidomide | Irene Ghobrial, MD | P3 | BB |
| Linvoseltamab | Regeneron Pharmaceuticals | P3 | BB |
| Daratumumab | Regeneron Pharmaceuticals | P3 | BB |
| Cyclophosphamide | Dana-Farber Cancer Institute | P2 | B |
| Melphalan | PETHEMA Foundation | P3 | B |
| Bortezomib | Omar Nadeem, MD | P2 | B |
+39 more in the Smoldering Plasma Cell Myeloma cohort
Other indications for CM336
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P3 | B · 63 |
| Plasma Cell Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. CM336 in Smoldering Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cm336-smoldering-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →